Results 171 to 180 of about 612,123 (266)

[Molecular targeted therapy for progressive low-grade gliomas in children]. [PDF]

Zhongguo Dang Dai Er Ke Za Zhi
Sun YL, Li M, Liu JJ, Gao WC, Wu YF, Wan LL, Ren SQ, DU SX, Wu WS, Sun LM.   +9 more
europepmc   +1 more source

Editorial: Molecular Targeted Therapy in Oncology: Lessons From Pharmacogenetics and Pharmacoepigenetics. [PDF]

Front Mol Biosci, 2022
Imani S, Becatti M, Khan MA.
europepmc   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

Molecular target therapy for malignant tumor 1) The molecular target therapy.

Nihon Naika Gakkai Zasshi, 2005
openaire   +2 more sources

Pathology confronts molecular targeted therapies [PDF]

Nature Clinical Practice Oncology, 2006
openaire   +2 more sources

Fournier's Gangrene in the Course of Treatment of Advanced Hepatocellular Carcinoma with Molecular-targeted Therapy. [PDF]

Intern Med
Komeda Y, Nagamatsu S, Kaya D, Sueki A, Yamamoto C, Ohta K, Matsuo Y, Nishio Y, Kikukawa S, Matsuura K, Matsuo H, Uejima M, Moriya K.   +12 more
europepmc   +1 more source

The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non-clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group database. [PDF]

Cancer Med, 2023
Koguchi T, Naito S, Hatakeyama S, Numakura K, Muto Y, Kato R, Kojima T, Kawasaki Y, Morozumi K, Kandori S, Kawamura S, Nishiyama H, Ito A, Habuchi T, Obara W, Ohyama C, Tsuchiya N, Kojima Y.   +17 more
europepmc   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

From molecular subgroups to molecular targeted therapy in rheumatoid arthritis: A bioinformatics approach. [PDF]

Heliyon
Xu Y, Yang Z, Wang T, Hu L, Jiao S, Zhou J, Dai T, Feng Z, Li S, Meng Q.   +9 more
europepmc   +1 more source

Treatment of Advanced Metastatic Prostate Cancer Using Molecular-Targeted Therapy: Radioligand Lutetium-177 Prostate-Specific Membrane Antigen. [PDF]

Cureus, 2023
Rathore R, Rangrej SB, Kieme I, Carvalho V, King K, Amadou Y, McKinley J, Masawi A.   +7 more
europepmc   +1 more source